元徵科技(02488.HK)將推動設備資產化及相關RWA應用的戰略佈局
格隆匯8月21日丨元徵科技(02488.HK)公吿,公司將結合現有業務積累與真實世界資產(RWA)領域技術,推動設備資產化及相關RWA應用的戰略佈局。
公司在區塊鏈和汽車數據領域具備深厚積累,已申請區塊鏈相關專利超過300項,累計通過汽車診斷設備與全球逾3.9億台車建立連接。據此,公司擬以部分高端產品系列(包括PAD系列汽車診斷設備、新能源車維修保養設備、ADAS校準設備、四輪定位設備等)資產為基礎,探索RWA應用的可行性,包括制定技術方案、增聘相關研發人員、與技術合作夥伴共同開發及部署技術平台,以及在合規前提下考慮申請相關業務試點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.